BofA analyst Alec Stranahan downgraded Y-mAbs Therapeutics (YMAB) to Underperform from Neutral with a price target of $3, down from $12.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
- Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
- Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
- Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist